Project Grant R37AI189285
Award Date 6/16/25
Completion Date 5/31/30
Dollars Obligated $1.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
- This Project Grant award of $1,657,972 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to characterize allogeneic T cell responses that may mediate a functional cure for HIV. The research, conducted by Oregon Health & Science University (OHSU), aims to define the allogeneic T cell responses and their targets in individuals cured of HIV after allogeneic hematopoietic stem cell...
- This federal Project Grant award of $800,389.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) aims to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The proposed treatment combines soluble IL-15/IL-15RA-FC with a TGF-beta pathway blockade and therapeutic vaccination to enhance and restore anti-viral immunity, with the goal of achieving sustained viral remission following...
- The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
- This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop novel chimeric antigen receptor (CAR) T-cell therapies to selectively target the PD-1+ HIV/SIV reservoir. The $862,398 award will fund research by the Fred Hutchinson Cancer Center to engineer CAR T-cell modalities that can be controlled by small molecule inhibitors or integrated into a link CAR...
- This $1,414,502 federal Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the distribution and penetration of antiretroviral (ARV) drugs within tissue reservoirs of HIV. Using advanced multimodal imaging techniques in a rhesus macaque animal model, the researchers aim to characterize the spatial distribution of ARV drugs, HIV virus, and host immune...
- This Project Grant award of $343,744 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of a comprehensive strategy for an Investigational New Drug (IND) submission and clinical development of a hematopoietic stem/progenitor cell-based chimeric antigen receptor (CAR) gene therapy to functionally cure HIV infection. The key products and services to be delivered include: 1) Formulating a strategic plan...
- The University of Pennsylvania received a $3,643,653 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The goal of this 5-year award is to generate a chimeric antigen receptor (CAR) approach that can control HIV viral replication and eliminate the viral reservoir, despite current antiretroviral therapies. The key elements of the proposal include: 1) Engineering...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $240,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Northwestern University to conduct research on characterizing HIV-1 viral reservoirs and the sources of residual viremia in people living with HIV-1 under antiretroviral therapy. The research aims to use novel techniques like viral immuno-capture and proviral sequencing to study the viral characteristics associated with...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,016,951 Project Grant titled "Reversing Effector-to-Memory Transition at ART Initiation to Impact the HIV Reservoir Towards ART-Free Control" (CFDA 93.855 - Allergy and Infectious Diseases Research) to The University of Texas MD Anderson Cancer Center. The project aims to use TGF-β blockade during antiretroviral therapy (ART) initiation to reverse the resting/quiescent status of T cells and support viral...
- This $197,366 Project Grant was awarded on March 1, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to identify the molecular mechanisms that control the natural, immune-mediated restriction of X4-tropic HIV virus, which typically emerges only in late-stage HIV disease when the immune system is impaired. The research will utilize primary CD4 T cells, in vivo analyses in...